Eighty-eight @entity1 with @entity43 underwent second-look laparotomy as part of their plan of management at Indiana University Hospital. Thirty-five @entity1 (39.8%) were found to have no gross or microscopic evidence of persistent @entity5 , and an additional 16 (18.2%) had only microscopic @entity5 . @entity1 with @entity5 were less likely to have negative findings at laparotomy than were @entity1 with Stage I or II disease. A complete initial cytoreductive operation (residual disease = 0 cm) correlated positively with negative findings at laparotomy. Endometrioid histologic findings were associated with a favorable condition at the second look, but @entity5 grade was associated with superior survival only for @entity1 with grade 0 disease. Eight of 30 @entity1 (26.7%) with @entity189 and negative findings at second-look laparotomy have had @entity5 recurrence (2 to 63 months), and five of eight have died. Intraperitoneal chromic @entity3151 salvage therapy for @entity1 with microscopic disease was promising, with eight of 15 treated @entity1 (53.3%) alive after therapy, with no evidence of disease from 16 to 56 months after the second look. Second-look laparotomy has been the major determinant of continued or alternative therapy for @entity1 with @entity43 . Second-look laparotomy has been incorporated into the standard management plan without a formal clinical trial. The need for a second look may be reduced by identifying @entity1 who do not benefit from the procedure. @entity1 with persistent disease confirmed by noninvasive means can continue therapy without laparotomy. There is also a subgroup of @entity1 with a favorable prognosis whose therapy could be safely discontinued without laparotomy.

Second-look laparotomy after chemotherapy in the management of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian malignancy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'initial Stage III or IV disease', 'neoplasm'] @entity189 :: ('MESH:D002277', 'Disease') :: ['invasive carcinoma'] @entity3151 :: ('MESH:D010758', 'Chemical') :: ['phosphorus']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian malignancy']
